

WEST PHARMACEUTICAL SERVICES INC
Form 8-K
January 14, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – January 15, 2009

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

| | | |
|---|------------------------------------|--|
| Pennsylvania (State or other jurisdiction of incorporation) | 1-8036 (Commission File Number) | 23-1210010 (IRS Employer Identification No.) |
| 101 Gordon Drive, PO Box 645, Lionville, PA (Address of principal executive offices) | | 19341-0645 (Zip Code) |

610-594-2900
(Registrant's telephone number, including area code)

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

“ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure

On January 5, 2009, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that Company Management will be presenting at the Sidoti & Company’s Sixth Annual Palm Beach Emerging Growth Institutional Investor Forum in Palm Beach, Florida on January 15, 2009. Donald E. Morel, Jr., Ph.D., Chairman & Chief Executive Officer will make the presentation and William Federici, Chief Financial Officer and Michael Anderson, Vice President and Treasurer will participate.

A copy of the Company’s presentation from the conference will be available for 30 days through the Investors link at the Company’s website, <http://www.westpharma.com> and is also attached hereto as Exhibit 99.2. A copy of the press release is attached hereto as Exhibit 99.1. Both Exhibits are incorporated herein by reference.

The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financials Statement and Exhibits

(d) Exhibits

| Exhibit # | Description |
|-----------|--|
| 99.1 | West Pharmaceutical Services, Inc. Press Release, dated January 5, 2009. |
| 99.2 | West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation). |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

John R. Gailey III
Vice President, General Counsel and Secretary

January 14, 2009

3

EXHIBIT INDEX

Description

- 99.1 West Pharmaceutical Services, Inc. Press Release, dated January 5, 2009.
- 99.2 West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation).

